Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Consider Another Punishment or Action against Novartis Pharma: Minister
September 3, 2014
- Yasuhisa Shiozaki Tapped as New Health Minister
September 3, 2014
- MHLW Will Discuss Freezing NHI Prices of Essential Drugs if Industry Requests It: MHLW Official Nakai
September 3, 2014
- MOF Official Unami Urges Full-Scale NHI Price Revision upon Next Sales Tax Hike
September 2, 2014
- METI to Request 20% Increase in Budget for Promotion of Science and Technology: FY2015 Budget Request
September 2, 2014
- MHLW to Reinforce Follow-Up Surveys on HPV Vaccine Recipients
September 1, 2014
- MHLW Prods Univ. of Tokyo to Set Up Third-Party Panel over J-ADNI
September 1, 2014
- MHLW Notifies Prefectures of RMP Submissions for Generics
August 29, 2014
- New Chuikyo Rep Abe Credits Key Premium for Accelerating Drug Development
August 29, 2014
- MHLW Notifies Health Professionals of Revised Package Insert for Simeprevir
August 28, 2014
- Chuikyo Grants Unprecedented 60% Premium to Ono’s Opdivo
August 28, 2014
- MHLW Calls for Maintenance of Current R&D Tax Credit Limit
August 27, 2014
- PFSB’s FY2015 Budget Request Seeks Funding to Increase PMDA Staff by 13 to Strengthen Its Consultation System
August 27, 2014
- MHLW’s FY2015 Budget Request at Record 31.67 Trillion Yen, Includes 74.8 Billion Yen to Promote Commercialization of Innovative New Drugs
August 27, 2014
- PAFSC Second Committee to Review Nobelpharma’s Anticancer Drug Streptozocin on Sept. 5
August 26, 2014
- MHLW to Promote Joint Drug Development by Pharmas, Academia
August 26, 2014
- PAFSC’s First Committee to Discuss Lixiana’s Additional Use on Sept. 4
August 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for August 11 - August 22
August 25, 2014
- PMDA Reviewing Lyrica for Risk of Fulminant Hepatitis, Hepatic Dysfunction
August 25, 2014
- Eisai Sues FDA over Shortened Exclusivity Time for Belviq, Fycompa
August 22, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…